ArticleWiener klinische Wochenschrift2026
Utility of combined detection of IgG/IgM/IgA vs. separate IgG and IgM antibodies to Anaplasma phagocytophilum in culture and PCR-confirmed patients with human granulocytic anaplasmosis.
Article in Wiener klinische Wochenschrift, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Sera from 26 patients from New York State with culture and PCR confirmed human granulocytic anaplasmosis (HGA) were used to assess the performance of three different immunofluorescence assays (IFA), combined IgG/IgA/IgM and separate IgM and IgG to detect acute and/or convalescent antibodies to Anaplasma phagocytophilum. Convalescent samples were obtained within 6 weeks of the acute sample. An IFA titer ≥ 80 was considered positive. Overall, 22 acute and 21 convalescent samples were tested by all 3 IFA assays.On the acute phase serum sample, 14/22 (63.6%) were positive using the combined IgG/IgA/IgM assay, 10/22 (45.5%) by IgM, 12/22 (54.5%) by IgG and 13/22 (59.1%) by either IgM or IgG assays. Only 1 of 8 (12.5%) samples testing negative by the combined IgG/IgA/IgM assay was positive by an individual IFA testing (IgM IFA only). Of the 21 cases with a convalescent phase sample, 100% tested positive on the combined IgG/IgA/IgM, 20 (95.2%) on the IgG and 20 (95.2%) on the IgM IFA individual assays; all 21 (100%) tested positive by either the IgM or the IgG individual IFA assays.Titers ≥ 640 were found in the acute phase in 58.3-80%, and in the convalescent phase for 85%-95.2% of the positive samples for the 3 IFA assays assessed.In conclusion, the 3 IFA methods tested had comparable sensitivity on acute and convalescent phase serum samples of patients with HGA when using a cut-off of ≥ 80. Further studies should be conducted to determine the IFA cut-off values that offer the best sensitivity and specificity.
Indexed as
Identifiers
42821100What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.